Research programme: LRRK2 protein inhibitors - Ipsen/Oncodesign

Drug Profile

Research programme: LRRK2 protein inhibitors - Ipsen/Oncodesign

Alternative Names: ODS 2005294; ODS200594

Latest Information Update: 27 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ipsen; Oncodesign Biotechnology
  • Class Small molecules
  • Mechanism of Action LRRK2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Parkinson's disease

Most Recent Events

  • 21 Oct 2015 Preclinical trials in Parkinson's disease in France (PO)
  • 18 Dec 2012 Oncodesign and the Katholieke Universiteit Leuven enter a collaboration to co-develop LRRK2 protein inhibitors for Parkinson's disease
  • 10 Jan 2012 Early research in Parkinson's disease in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top